Researchers have linked a debilitating neurological disease in children to mutations in a gene that regulates neuronal development through control of protein movement within neuronal cells.
The Montreal Neurological Institute and Hospital - The Neuro, McGill University and the McGill University Health Centre, is at the forefront of Parkinson’s research and clinical care. Parkinson’s patients are seen at The Neuro’s Movement Disorders Clinic and the Montreal General Hospital. Approximately 100,000 Canadians have Parkinson’s disease.
The Neuro to introduce experimental drug treatment
$1 M gift from Mr. J. Sebastian van Berkom launches translational research into neurological disease
A patient’s very own skin cells may hold the key to new treatments and even cures for devastating neurological diseases. A generous $1 million donation from Mr. J. Sebastian van Berkom, and critical partnerships with Brain Canada, Laval University, Marigold Foundation and the FRQS-Réseau Parkinson Quebec are driving an innovative, iPSC (induced pluripotent stem cell) research platform that will transform research into Parkinson’s and other neurological diseases.
The Neuro has been at the forefront of epilepsy treatment and research for over half a century. The “Montreal Procedure” developed by Dr. Wilder Penfield and colleagues revolutionized the surgical treatment for epilepsy, allowing thousands of patients to start new lives free of seizures. The use of electroencephalography (EEG) and magnetic resonance imaging (MRI) for the study and treatment of epilepsy was pioneered at The Neuro.
Amyotrophic lateral sclerosis (ALS), also known as “Lou Gehrig’s Disease,” is a devastating fatal disease of the nervous system that kills two to five Canadians every day. On September 19th and 20th, the Montreal Neurological Institute and Hospital (The Neuro), at McGill University and the McGill University Health Centre will host the 10th Annual ALS Symposium of the Fondation André-Delambre. Nearly one hundred researchers and clinicians from several countries will come together to discuss recent progress in ALS research.
An international team of researchers has discovered a significant genetic component of Idiopathic Generalized Epilepsy (IGE), the most common form of epilepsy. Epilepsy is a neurological disorder characterized by sudden, uncontrolled electrical discharges in the brain expressed as a seizure. The new research, published in this week’s issue of EMBO Reports, implicates a mutation in the gene for a protein, known as cotransporter KCC2.
What is ALS?
People with schizophrenia often misinterpret what they see and experience in the world. New research provides insight into the brain mechanisms that might be responsible for this misinterpretation.
A new study shows that memory pathology in older mice with Alzheimer’s disease can be reversed with treatment. The study by researchers from the Montreal Neurological Institute and Hospital - The Neuro, at McGill University and at Université de Montréal found that blocking the activity of a specific receptor in the brain of mice with advanced Alzheimer’s disease (AD) recovers memory and cerebrovascular function. The results, published in the Journal of Neuroinflammation in May, also suggest an underlying mechanism of AD as a potential target for new therapies.
What is ALS?
Amyotrophic Lateral Sclerosis (ALS) also known as Lou Gehrig’s disease, is a neurodegenerative disease in which progressive muscle weakness leads to paralysis. ALS is a result of the death of motor neurons (nerve cells) in the brain and spinal cord that control voluntary muscle movement. Most people survive less than five years following diagnosis, but a small percentage of patients live for ten years or even longer. So far, there is no cure. About 3,000 Canadian adults have ALS and less than 1 in 10 patients have a family history of the disease.
Dr. Robert J.
Research opens door to new drug therapies for Parkinson’s disease
January 29, 2013 - Addiction to cigarettes, drugs and other stimulants has been linked in the past to the brain’s frontal lobes, but now there is scientific evidence that indicates where in the frontal cortex addiction takes hold and how. Addiction could be a result of abnormal communication between two areas of the frontal lobes linked to decision-making. The discovery will undoubtedly stimulate clinical work on new therapies for millions of people who suffer from addiction.
January 28, 2013 - A revolutionary technology has the ability to detect and diagnose Alzheimer’s disease with unprecedented accuracy. The computerized technique known as SNIPE analyzes magnetic resonance imaging (MRI) scans to capture patterns of atrophy specific to the disease in brain structures, specifically the hippocampus and entorhinal cortex. Diagnosing Alzheimer’s disease (AD) is still an inexact science, relying mainly on the patient's symptoms and performance on memory tests. Detecting pre-clinical AD, before symptoms appear, is extremely difficult.
November 8 2012 - After a worldwide search, the renowned Montreal Neurological Institute and Hospital – The Neuro – of McGill University and the McGill University Health Centre has a new director, Guy Rouleau, MD, PhD, FRCPC, OQ. Dr. Rouleau, a prominent Quebec clinician-scientist recognized for his contributions to science and society, will also hold the Wilder Penfield Chair in Neuroscience as Professor of Neurology and Neurosurgery at McGill. The appointment takes effect January 1, 2013.